Compare RMBS & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMBS | CRL |
|---|---|---|
| Founded | 1990 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.0B |
| IPO Year | 1997 | 1999 |
| Metric | RMBS | CRL |
|---|---|---|
| Price | $134.05 | $169.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $137.00 | ★ $198.27 |
| AVG Volume (30 Days) | ★ 2.4M | 711.6K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.88 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | $707,630,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $16.23 | $3.04 |
| P/E Ratio | $234.94 | ★ N/A |
| Revenue Growth | ★ 27.13 | 10.48 |
| 52 Week Low | $52.18 | $132.58 |
| 52 Week High | $161.80 | $228.88 |
| Indicator | RMBS | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 45.96 |
| Support Level | $90.31 | $161.39 |
| Resistance Level | $161.80 | $184.75 |
| Average True Range (ATR) | 9.22 | 8.05 |
| MACD | -0.26 | 0.09 |
| Stochastic Oscillator | 51.57 | 22.85 |
Rambus Inc is a semiconductor company providing chips and silicon IP for data-intensive computing systems, focusing on data center and artificial intelligence (AI) infrastructure. The company is at the forefront of enabling the next era of AI-driven computing, addressing challenges of signal and power integrity at increasingly extreme data rates across the data center, edge, and client markets. It offers high-performance memory subsystems, with a balanced and diverse portfolio of products, IP, and patents that maximize performance and security in computationally intensive systems. The company operates in South Korea, Singapore, the United States, and other countries, with the majority of its revenue coming from South Korea.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.